SCHEMBL3807705

SCHEMBL3807705

CP(=O)(Oc1ccc(-c2oc3cc(O)cc(O)c3c(=O)c2O)cc1O)Oc1ccc(-c2oc3cc(O)cc(O)c3c(=O)c2O)cc1O

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 8/20 0.75
CYP1A1 P04798 7/20 0.75
CYP1B1 Q16678 7/20 0.75
MEN1 O00255 9/20 0.66
KMT2A Q03164 9/20 0.66
ABCB1 P08183 7/20 0.66
XDH P47989 6/20 0.66
CYP3A4 P08684 6/20 0.66
CYP2C9 P11712 5/20 0.66
IPMK Q8NFU5 5/20 0.66
IP6K2 Q9UHH9 5/20 0.66
KDM4E B2RXH2 5/20 0.66
HSD17B10 Q99714 5/20 0.66
FTO Q9C0B1 5/20 0.66
MAPT P10636 5/20 0.66
AKR1B1 P15121 5/20 0.66
ALOX15 P16050 4/20 0.66
HIF1A Q16665 4/20 0.66
DPP4 P27487 4/20 0.66
CA12 O43570 4/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL118117 0.92 CYP1A2 (0.73) CYP1A2CYP1A1CYP1B1MEN1KMT2A
SCHEMBL117527 0.90 CYP1A2 (0.73) CYP1A2CYP1A1CYP1B1MEN1KMT2A
Tamarixetin SCHEMBL30255798 0.86 CYP1A2 (1.00) CYP1A2CYP1A1CYP1B1MEN1KMT2A
Tamarixetin SCHEMBL29750609 0.86 CYP1A2 (1.00) CYP1A2CYP1A1CYP1B1MEN1KMT2A
Tamarixetin SCHEMBL892776 0.86 CYP1A2 (1.00) CYP1A2CYP1A1CYP1B1MEN1KMT2A
SCHEMBL3718645 0.84 MAPT (0.66) CYP1A2CYP1A1CYP1B1MEN1KMT2A
SCHEMBL117682 0.83 CYP1A2 (0.73) CYP1A2CYP1A1CYP1B1MEN1KMT2A
SCHEMBL3718781 0.83 MEN1 (0.74) CYP1A2CYP1A1CYP1B1MEN1KMT2A
SCHEMBL3807697 0.82 CYP1A2 (0.72) CYP1A2CYP1A1CYP1B1MEN1KMT2A
SCHEMBL13056264 0.82 CYP1A2 (0.69) CYP1A2CYP1A1CYP1B1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100297020-A1 PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT LIMERICK BIOPHARMA, INC. (US) 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297020-A1 PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT PC, PCK1, PYGL CYP1A2 2311/4885CYP1A1 2951/4885CYP1B1 3193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.